HCC827-Luc

HCC827-Luc is a bioluminescent derivative of the human HCC827 lung adenocarcinoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental HCC827 cell line was established from a lung adenocarcinoma and is notable for harboring an activating EGFR exon 19 deletion (del E746-A750), which confers high sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and osimertinib. HCC827 is therefore one of the most widely used preclinical models for studying EGFR-driven lung cancer biology, mechanisms of acquired TKI resistance, and the efficacy of next-generation targeted therapies.

The stable luciferase integration in HCC827-Luc enables sensitive, quantitative bioluminescence imaging (BLI) of tumor burden in xenograft and orthotopic lung tumor models in immunocompromised hosts. The emitted luminescent signal correlates with viable tumor cell number, supporting noninvasive longitudinal monitoring of tumor engraftment, growth kinetics, metastatic dissemination, and therapeutic response. This makes HCC827-Luc particularly suitable for evaluating the efficacy of EGFR-targeted agents, combination therapies, and resistance-reversal strategies in preclinical in vivo settings.

HCC827-Luc retains the key molecular and phenotypic features of the parental HCC827 line, including EGFR exon 19 deletion status and sensitivity to approved EGFR inhibitors. The luciferase modification substantially enhances experimental sensitivity and throughput, enabling real-time pharmacodynamic assessments and facilitating both high-throughput drug screening and mechanistic investigations of EGFR pathway biology. Researchers should verify luciferase activity, EGFR mutation status, and growth kinetics under their specific experimental conditions prior to use in quantitative imaging or pharmacological studies.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

7. Follow the procedure described under Post-Thaw Recovery

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.